ClinicalTrials.gg
Not yet recruitingNCT07317557RIC-CSVDUpdated Mar 10, 2026

Remote Ischemic Conditioning for Cognitive Impairment in Cerebral Small Vessel Disease

An interventional study of Remote ischemic conditioning using IPC-906 device and Sham remote ischemic conditioning using IPC-906 device in Cerebral Small Vessel Disease and Cognitive Impairment, sponsored by Jiangsu Province Nanjing Brain Hospital. Not yet recruiting at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Jiangsu Province Nanjing Brain Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Cerebral Small Vessel Diseases with a site in China — 32 open to participants now, 33 under way, 1 of them phase 3. Cerebral Small Vessel Diseases · China.

Planned enrollment
25th of 26
40 · median 105
Started
2026
with 4 others
No phase
16 of 48
9 open now
Primary completion
2026-12
later than 11 of 32 live
Registered
43rd of 48
by date

Among the 48 studies in Cerebral Small Vessel Diseases with a site in China, this one is the 25th largest by planned enrollment of the 26 interventional ones that give a count, is one of 5 that started in 2026, is one of 16 with no phase, reaches primary completion later than 11 of the 32 other live ones, and was the 43rd registered.

Cerebral Small Vessel Diseases

128 studies on the registry are indexed under Cerebral Small Vessel Diseases; 71 are open to participants now.

Browse Cerebral Small Vessel Diseases studies →

Open to participants now

32 of the 48 studies in Cerebral Small Vessel Diseases with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Cerebral Small Vessel Diseases studies recruiting now, 26 (57%) set no upper age limit and 5 (11%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Cerebral Small Vessel Diseases with a site in China, or all of them as a file.
02

Study summary

This randomized, double-blind, sham-controlled trial aims to evaluate the effect of remote ischemic conditioning (RIC) on cognitive function in patients with cerebral small vessel disease-related mild cognitive impairment. Forty eligible participants will be randomized 1:1 to receive either RIC or sham RIC twice daily for 90 days in addition to standard medical therapy. The primary outcome is the change in Montreal Cognitive Assessment (MoCA) score from baseline to 90 days. Secondary outcomes include changes in white matter hyperintensity burden and diffusion tensor imaging metrics on MRI, EEG functional connectivity, and activities of daily living.

Read the detailed description

Cerebral small vessel disease (CSVD) is a leading cause of vascular cognitive impairment, characterized by white matter hyperintensities, lacunes, and microbleeds on MRI. Current treatment options for CSVD-related cognitive impairment are limited, and there is a critical need for safe, noninvasive interventions that can improve cognitive function and delay disease progression.

Remote ischemic conditioning (RIC) is a noninvasive, low-cost procedure induced by intermittent cuff inflation on a limb to produce brief episodes of ischemia and reperfusion. Experimental and clinical studies suggest that RIC can improve cerebral perfusion, protect the neurovascular unit, and modulate inflammatory and endothelial pathways, making it a promising strategy for CSVD.

In this single-center, randomized, double-blind, sham-controlled trial, we will enroll 40 patients with CSVD-related mild cognitive impairment. Participants will be randomized to receive either RIC (cuff inflation to 200 mmHg for 5 minutes followed by 5 minutes of reperfusion, 5 cycles per session) or sham RIC (cuff inflation to 60 mmHg, 5 cycles per session). The intervention will be administered twice daily for 90 days, in addition to standard medical therapy.

Cognitive function will be assessed by the Montreal Cognitive Assessment (MoCA). MRI will be used to quantify white matter hyperintensities and diffusion tensor imaging parameters, and EEG will be used to evaluate functional connectivity. Activities of daily living and safety outcomes will also be recorded. This study will provide clinical and mechanistic evidence on whether RIC can prevent or ameliorate cognitive impairment in patients with CSVD.

03

Conditions studied

  • Cerebral Small Vessel Disease
  • Cognitive Impairment

Keywords

  • cerebral small vessel disease; cognitive impairment; remote ischemic conditioning; white matter hyperintensities; EEG functional connectivity
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 30-80 years.
  • Diagnosis of cerebral small vessel disease according to the Chinese Guidelines for the Diagnosis and Treatment of Cerebral Small Vessel Disease (2020).
  • Mild cognitive impairment with a (MoCA) score of 18-25.
  • The patient or a legally authorized representative is able and willing to sign written .

Exclusion criteria

Exclusion Criteria:

  • Any condition that is unsuitable for remote ischemic conditioning, including soft tissue injury, limb deformity or vascular injury in the upper limb, bleeding disorders, or systolic blood pressure > 200 mmHg.
  • History or presence of neurological or psychiatric disorders that may interfere with participation or outcome assessment, such as other cerebrovascular diseases, Parkinson's disease, or major depressive disorder.
  • Current or past severe systemic diseases deemed inappropriate for the study by the investigator, including but not limited to severe cardiovascular diseases (e.g., congestive heart failure, severe arrhythmia, myocardial infarction), severe hepatic diseases (e.g., cirrhosis), severe renal diseases (e.g., requiring hemodialysis or peritoneal dialysis), hematologic diseases with bleeding tendency (e.g., hemophilia), poorly controlled diabetes (blood glucose > 16.8 mmol/L or \< 2.8 mmol/L) or with severe complications, active or uncontrolled systemic diseases or primary/secondary immunodeficiency, or .
  • Laboratory abnormalities, including \< 1.5 × 10⁹/L, count \< 100 × 10⁹/L, \< 90 g/L, or ALT > 2.5 × (ULN), total > 1.5 × ULN, or serum creatinine > 1.5 × ULN.
  • Coagulation abnormalities, including for patients not on anticoagulant/antithrombotic therapy: > 1.7 or APTT > 1.25 × ULN; and for patients on anticoagulant/antithrombotic therapy: INR > 3.0 or APTT > 1.5 × ULN.
  • Positive tests for with detectable HBV-DNA, or positive serology for , syphilis (TPAb/RPR), or .
  • Pregnant or breastfeeding women.
  • to MRI (e.g., pacemaker or other metallic implants, severe claustrophobia).
  • Participation in another clinical trial within 3 months prior to enrollment.
  • Severe trauma or major surgery within 3 months before remote ischemic conditioning, or planned surgery during the study period (except minor procedures and laparoscopic procedures performed within 4 weeks before baseline).
  • History of substance abuse or alcoholism within 1 year prior to enrollment.
  • Any other condition that may increase risk or interfere with the interpretation of study results, as judged by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Remote ischemic conditioning

    Remote ischemic conditioning plus standard medical therapy.

    Device: Remote ischemic conditioning using IPC-906 device

  • Sham comparator
    Sham remote ischemic conditioning

    Sham remote ischemic conditioning plus standard medical therapy

    Device: Sham remote ischemic conditioning using IPC-906 device

Interventions

  • DeviceRemote ischemic conditioning using IPC-906 device

    A pneumatic cuff is placed on one upper limb and inflated to 200 mmHg for 5 minutes followed by 5 minutes of reperfusion, repeated for 5 cycles (total 45 minutes) per session, twice daily for 90 days, in addition to standard medical therapy.

  • DeviceSham remote ischemic conditioning using IPC-906 device

    The same cuff procedure is applied, but cuff pressure is set at 60 mmHg, which does not induce ischemia. The schedule is identical: 5 minutes inflation and 5 minutes reperfusion, 5 cycles (45 minutes) per session, twice daily for 90 days, in addition to standard medical therapy.

06

What researchers measure

Primary outcomes

  1. Change in Montreal Cognitive Assessment (MoCA) score from baseline to 90 days.

    The primary endpoint is the difference in mean MoCA score change from baseline to 90 days between the remote ischemic conditioning group and the sham group.

    Time frame: Baseline and 90 days after randomization.

Secondary outcomes

  1. Change in total white matter hyperintensity (WMH) volume on brain MRI (milliliters).

    Total WMH volume (mL) will be quantified on 3D T2-FLAIR brain MRI using semi-automated volumetric segmentation and normalized to intracranial volume. The outcome is the change in total WMH volume from baseline to 90 days between the two groups.

    Time frame: Baseline and 90 days.

  2. Change in mean diffusivity (MD) of cerebral white matter on diffusion tensor MRI (×10-³ mm²/s).

    Mean diffusivity (×10-³ mm²/s) will be calculated from diffusion tensor imaging in predefined cerebral white matter regions of interest. The outcome is the change in MD from baseline to 90 days between the two groups.

    Time frame: Baseline and 90 days.

  3. Change in fractional anisotropy (FA) of cerebral white matter on diffusion tensor MRI.

    Fractional anisotropy values in predefined cerebral white matter regions will be derived from diffusion tensor imaging. The outcome is the change in FA from baseline to 90 days between the two groups.

    Time frame: Baseline and 90 days.

  4. Change in axial diffusivity (AD) of cerebral white matter on diffusion tensor MRI (×10-³ mm²/s).

    Axial diffusivity (×10-³ mm²/s) in predefined cerebral white matter regions will be obtained from diffusion tensor imaging. The outcome is the change in AD from baseline to 90 days between the two groups.

    Time frame: Baseline and 90 days.

  5. Change in radial diffusivity (RD) of cerebral white matter on diffusion tensor MRI (×10-³ mm²/s).

    Radial diffusivity (×10-³ mm²/s) in predefined cerebral white matter regions will be obtained from diffusion tensor imaging. The outcome is the change in RD from baseline to 90 days between the two groups.

    Time frame: Baseline and 90 days.

  6. Change in EEG global functional connectivity (graph-theoretical global efficiency index).

    Weighted functional connectivity matrices will be constructed from resting-state EEG signals, and graph-theoretical global efficiency (dimensionless) will be calculated as a summary index of whole-brain functional connectivity. The outcome is the change in global efficiency from baseline to 90 days between the two groups.

    Time frame: Baseline and 90 days.

  7. Change in Activities of Daily Living (ADL) scale score.

    The Activities of Daily Living Scale (ADL) is a \[\[X-item\]\] questionnaire assessing basic daily self-care abilities. Each item is scored from \[\[A\]\] to \[\[B\]\] points, yielding a total score ranging from \[\[0\]\] to \[\[100\]\] points. Higher scores indicate worse activities of daily living (greater functional impairment). The outcome is the change in ADL total score from baseline to 90 days between the two groups.

    Time frame: Baseline and 90 days.

  8. Incidence of adverse events related to remote ischemic conditioning.

    Including skin petechiae, bruising, limb discomfort or numbness, and any serious adverse events.

    Time frame: Baseline to 90 days.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — There is no current plan to share individual participant data (IPD) from this trial with external researchers. De-identified, aggregate study results will be reported in publications and presentations in accordance with institutional and national regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Jan 5, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07317557
Lead sponsor
Jiangsu Province Nanjing Brain Hospital
Responsible party
Sponsor
First posted
Jan 5, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 10, 2026

Study contacts

Xiaoyin wang, MD
Contact
cherryhfkaku2011@163.com
+86 18810650523
Xiaoyin Wang, MD
principal investigator · Department of Neurology, Nanjing Brain Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion